Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01439282 · ClinicalTrials.gov registry record · Phase 2
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase 2 study of Breast Cancer and Estrogen Receptor Positive Tumor, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
- 20
- Study locations
NCT01439282 is a Phase 2 study of Breast Cancer and Estrogen Receptor Positive Tumor that has completed, run by Eisai. The registered enrollment target is 77 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT01439282, a Phase 2 study of Breast Cancer and Estrogen Receptor Positive Tumor, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, multicenter, single-arm, feasibility study evaluating eribulin in combination with capecitabine as an adjuvant chemotherapy regimen in approximately 65 subjects with early-stage (I-II), human epidermal growth factor receptor 2 (HER2)- normal, estrogen receptor (ER)-positive breast cancer.
Conditions Studied
Interventions
- DRUG capecitabine
- DRUG eribulin mesylate
Study Locations (20)
Texas
- Texas Oncology-Austin Central - Austin
- Texas Oncology-Medical City Dallas - Dallas
- Texas Oncology-Dallas Presbyterian Hospital - Dallas
- Texas Oncology-Methodist Charlton Cancer Center - Dallas
- Texas Oncology-Baylor Charles A. Sammons Cancer Center - Dallas
- Texas Oncology- Denton South - Denton
- Texas Oncology-Fort Worth 12th Ave. - Fort Worth
- Texas Oncology-Memorial City - Houston
- Texas Oncology-Lewisville - Lewisville
- Texas Oncology-Paris - Paris
- Cancer Care Centers of South Texas - San Antonio
- Texas Oncology-Tyler - Tyler
Arizona
- Arizona Oncology Associates, PC - HOPE - Tucson
- Arizona Oncology Associates, PC - CASA - Tucson
New York
- New York Oncology Hematology, P.C. - Albany
- Sciode Medical Associates, PLLC, d.b.a. Eastchester Center - The Bronx
Florida
- Cancer Centers of Florida - Orlando
Georgia
- Northwest Georgia Oncology Centers, P.C. - Marietta
South Carolina
- Cancer Centers of the Carolinas - Greenville
Virginia
- Virginia Oncology Associates - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2011-08 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01439282
The ClinicalTrials.gov registry entry for NCT01439282 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which capecitabine is the first listed.
NCT01439282 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Texas, Arizona, New York.
Frequently Asked Questions
What is clinical trial NCT01439282 about?
NCT01439282 is a clinical study titled "Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer". This is a Phase 2, multicenter, single-arm, feasibility study evaluating eribulin in combination with capecitabine as an adjuvant chemotherapy regimen in approximately 65 subjects with early-stage (I-II), human epidermal growth factor receptor 2 (HER2)- normal, estrogen receptor (ER)-positive breast...
What is the current status of trial NCT01439282?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2011-08. Estimated completion is 2014-05.
What conditions does trial NCT01439282 study?
This clinical trial studies the following conditions: Breast Cancer, Estrogen Receptor Positive Tumor.
What interventions are being tested in trial NCT01439282?
The interventions under investigation include: capecitabine (DRUG), eribulin mesylate (DRUG).
Who is sponsoring clinical trial NCT01439282?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01439282 being conducted?
This trial has 20 study locations across Arizona, Florida, Georgia, New York, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.